Company

The company

EPICS Therapeutics is developing a novel class of RNA-based therapeutics with the potential to effectively treat a wide range of cancers.

Despite advancements in omics technologies, we have not seen the expected surge in new cancer-reversing medicines approved by the FDA.

The main obstacle we face is the complexity of proteomics and genomics data.

We believe acting at the mRNA level presents the best opportunity for success. The epitranscriptome, which encompasses around 170 mRNA modifications, offers a manageable number of targets.

Revolution

The revolution

Our approach: we focus on epigenetic RNA modifications, which represent a manageable number of variables.

By targeting the enzymes that modulate mRNA levels at the epigenetic level, we can selectively influence the pathways and proteins that are dysregulated in cancer cells, minimizing the impact on normal cells.

METTL3 methyltransferase is the key enzyme responsible for m6A transfer, the most abundant mRNA modification. m6A modification has been linked to tumor growth, invasion, and metastasis.

Program

Our program

We have established a promising pipeline of small molecule mRNA modulators addressing critical areas of unmet medical need.

Our lead program targets METTL3 methyltransferase for AML and solid tumors. 

METTL3 is the most validated RNA epigenetic target, and we demonstrated that our METTL3 inhibitor is effective in vitro and in vivo.

Science

Science

We have a best-in-class METTL3 inhibitor 

METTL3 methyltransferase is the key enzyme responsible for m6A transfer, the most abundant mRNA modification.

m6A modification has been linked to tumor growth, invasion, and metastasis.

  • Overexpressed in many liquid and solid tumors
  • High expression predicts poor survival
  • knockdown of METTL3 slows tumor growth
  • m6A is a downstream marker of METTL3 activity
  • Decreased m6A correlates to decreased tumor growth

Key Figures

Our team

Our team

Meet our team of drug development experts

Careers

Careers

Working with us

We are seeking people who share our passion and purpose of pushing the boundaries of medicine. EPICS Therapeutics team members are innovative and collaborative, working together toward the goal of providing treatments to patients in need.

Contact

Contact

47 Rue Adrienne Bolland
6041 Gosselies, Belgium
VAT : BE 0690 759 071
+32 71 348 500
Info@epicstx.com